Latest Ratios: P/E Ratio -5.7x · EV/EBITDA N/A · ROE -16.7%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $223M | $488M | $617M | $175M | $92M | $297M | $432M | $232M | $342M | $194M | $211M |
| Enterprise Value | $136M | $401M | $483M | $221M | $113M | $380M | $459M | $271M | $418M | $331M | $371M |
| P/E Ratio → | -5.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.64 | 5.72 | 3.54 | 1.65 | 0.94 | 2.28 | 3.13 | 1.98 | 3.03 | 1.91 | 2.02 |
| P/B Ratio | 0.51 | 1.15 | 1.31 | — | — | 3.14 | 3.11 | 1.51 | 4.74 | 6.28 | 3.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.70 | 2.77 | 2.08 | 1.15 | 2.91 | 3.32 | 2.31 | 3.70 | 3.25 | 3.55 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.9% | 49.9% | 48.3% | 47.4% | 37.8% | 53.1% | 60.3% | 54.8% | 54.6% | 51.0% | 55.9% |
| Operating Margin | -109.3% | -109.3% | -100.5% | -72.0% | -118.6% | -51.7% | -36.9% | -44.2% | -42.6% | -57.3% | -70.1% |
| Net Profit Margin | -87.8% | -87.8% | -79.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% | -52.2% | -59.4% | -72.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.7% | -16.7% | -85.8% | — | -2895.8% | -50.7% | -36.2% | -57.4% | -114.5% | -143.8% | -90.4% |
| ROA | -12.7% | -12.7% | -29.7% | -20.9% | -57.1% | -19.7% | -18.0% | -22.8% | -20.0% | -20.4% | -22.4% |
| ROIC | -20.7% | -20.7% | -111.2% | — | -148.1% | -29.4% | -21.4% | -22.8% | -22.8% | -23.0% | -22.2% |
| ROCE | -18.6% | -18.6% | -46.1% | -27.3% | -40.6% | -27.2% | -20.3% | -20.8% | -18.5% | -22.0% | -23.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.07 | — | — | 1.18 | 0.69 | 0.39 | 2.39 | 6.31 | 3.66 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.28 | — | — | 0.88 | 0.19 | 0.25 | 1.06 | 4.43 | 3.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3718.31 | -3718.31 | -40.71 | -15.25 | -43.55 | -15.65 | -14.15 | -14.59 | -3.42 | -9.95 | -12.78 |
Net cash position: cash ($118M) exceeds total debt ($31M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.19 | 4.19 | 5.70 | 1.45 | 4.81 | 1.45 | 2.17 | 2.93 | 3.38 | 2.83 | 3.28 |
| Quick Ratio | 4.01 | 4.01 | 5.09 | 1.26 | 4.31 | 1.03 | 1.81 | 2.50 | 3.04 | 2.38 | 2.60 |
| Cash Ratio | 1.73 | 1.73 | 4.44 | 1.05 | 3.82 | 0.57 | 1.26 | 1.79 | 2.54 | 1.89 | 2.01 |
| Asset Turnover | — | 0.15 | 0.28 | 0.33 | 0.25 | 0.47 | 0.43 | 0.44 | 0.37 | 0.35 | 0.34 |
| Inventory Turnover | 2.14 | 2.14 | 2.21 | 2.72 | 2.84 | 2.94 | 2.78 | 3.81 | 3.95 | 3.31 | 2.29 |
| Days Sales Outstanding | — | 57.45 | 70.32 | 67.48 | 64.39 | 51.21 | 67.17 | 59.09 | 53.80 | 53.89 | 51.06 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 6.6% | 3.1% | 0.8% | 0.6% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $382M | $353M | $79M | $78M | $76M | $72M | $67M | $40M | $33M | $29M |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LAB stock.
Standard BioTools Inc.'s current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.
Standard BioTools Inc.'s return on equity (ROE) is -16.7%. The historical average is -58.3%.
Based on historical data, Standard BioTools Inc. is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Standard BioTools Inc. has 49.9% gross margin and -109.3% operating margin.
Key Metrics
Top Statement Risk
Persistent operating losses and cash burn
Metrics are mathematically derived from official filings.
Discount to Book Reflects Earnings Doubt
Based on reported figures, LAB trades at 0.57 times book value and 2.92 times sales, a discount to book that suggests the market is pricing in continued losses and possible asset impairment rather than an earnings recovery.
With trailing P/E at -3.18 and no positive earnings base to anchor EV/EBITDA, price-to-book and price-to-sales are the only usable valuation signals, and the negative operating margin of -102.0% in 2026Q3 limits their reliability. The sub-1.0 P/B, set against a shrinking asset base and retained earnings near -$1.1B, may indicate that investors doubt the book value of equity will be realized through operations. Investors should monitor whether quarterly revenue stabilization near $19M to $21M can translate into positive operating income before the multiple can be considered meaningful.
Positive Net Margin Is Non-Operating Noise
As reported in the income statements, LAB posted a 69.6% net margin in 2026Q3 while its operating margin stayed at -102.0%, indicating the bottom-line result is driven by items outside core operations rather than improved earning power.
Gross margin ranged between 43.0% and 55.9% across the ten quarters, which is respectable for a tools business, yet operating margin has remained deeply negative throughout, so gross profit is consistently consumed by operating expenses. The 2026Q3 net margin reversal from -133.1% in the prior quarter to +69.6% appears to reflect non-recurring or non-operating gains and should not be read as evidence of sustainable profitability. Operating margin remains the more reliable measure of earning power here, and it is firmly negative.
Negative ROIC Persists Despite Asset Shrinkage
Based on LAB's reported quarterly figures, ROIC has remained negative across all ten quarters, ranging from -2.1% to -7.0%, suggesting the company has not yet generated returns above its cost of capital on the invested base.
The shrinking asset base and declining debt have not translated into improving returns, indicating that capital is being consumed faster than it is being redeployed productively. ROE swung between -9.2% and +4.7% without a sustained upward trend, which implies equity returns are driven more by volatile non-operating results than by operating improvement. Until operating margins turn positive, ROIC is unlikely to recover durably, and investors should monitor whether asset reduction stabilizes the denominator.
Low Leverage Offsets Absent Interest Coverage
As reported in the balance sheets, LAB's debt-to-equity fell from 0.18 in 2024Q3 to 0.05 in 2026Q3, yet interest coverage is not meaningful given negative operating income, so debt service capacity cannot be assessed from earnings.
Debt has been reduced substantially, which lowers refinancing and covenant pressure relative to the prior period, making this the most favorable leverage trend in the dataset. Interest coverage ratios are either blank or deeply negative, so the company cannot service debt from operating earnings and must rely on its cash balance of roughly $267.5M. Because the data does not disclose debt maturities or covenant terms, any conclusion about refinancing risk remains speculative and warrants further investigation.
Cash Cushion Thins Under Sustained Burn
Based on reported figures, LAB's current ratio of 9.75 and quick ratio of 9.40 in 2026Q3 appear strong, but these levels rest on a cash balance that declines with each quarter of operating cash outflow.
The high current ratio is largely supported by cash and receivables relative to $79.6M of total liabilities, which makes near-term liquidity look substantial on a static basis. Operating cash outflows in most quarters, including -$56.9M in 2026Q2, mean the cushion is being drawn down rather than replenished, and a 185-day cash conversion cycle in 2026Q3 suggests working capital is tied up for long periods. Under continued burn at prior-year rates, the liquidity runway would shorten meaningfully, so investors should monitor quarterly cash movement closely.
Headline Liquidity Overstates Durable Strength
As reported in the balance sheets, LAB's 9.75 current ratio may overstate resilience, since the ratio is supported by a cash balance that is being consumed by operating outflows and a retained deficit near -$1.1B.
A bullish reading would point to the 0.05 debt-to-equity and the 9.75 current ratio as evidence of a fortress balance sheet, but these figures describe a snapshot rather than a durable earnings base. The deficit suggests equity has been funded largely by paid-in capital, which may understate future dilution exposure if burn persists. Investors should weigh whether the cash runway, not the static ratios, is the binding constraint on the equity thesis.